RecruitingNot ApplicableNCT06894992

Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment

A Comparison of The Effectiveness of Tegoprazan and Lansoprazole in Achieving Cure Rates in Patients With Bleeding Peptic Ulcers: A Double-Blind Randomized Trial


Sponsor

Mario Steffanus

Enrollment

162 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are: How does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate bleeding peptic ulcer patients in the Indonesian population? Researchers will compare the drug tegoprazan to lansoprazole with a double-blind randomized control to see their effect on healing bleeding peptic ulcers. Participants will: Take drug tegoprazan 50 mg OD or lansoprazole 30 mg OD every day for 2 weeks Endoscopic examination at the beginning before treatment and after completion of treatment within 2 weeks Record of their adverse effect occurrence


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination

Exclusion Criteria6

  • Allergic to Tegoprazan or Lansoprazole
  • Diagnosed with gastric or duodenal cancer, pregnant
  • History of H. pylori infection treatment failure
  • Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis
  • Alcohol consumption
  • Undergoing chemotherapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTegoprazan

Tegoprazan 50 mg tab PO OD in 2 weeks

DRUGLansoprazole

Lansoprazole 30 mg tab PO OD in 2 weeks


Locations(2)

Cipto Mangunkusumo National General Hospital

Jakarta, DKI Jakarta, Indonesia

Atma Jaya Hospital

Jakarta, DKI Jakarta, Indonesia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06894992